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IMPORTANCE Existing data regarding the association between delayed initiation of
antimicrobial therapy and the development of renal scarring are inconsistent.
OBJECTIVE To determine whether delay in the initiation of antimicrobial therapy for febrile
urinary tract infections (UTIs) is associated with the occurrence and severity of renal scarring.
DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study that combined data from
2 previously conducted longitudinal studies (the Randomized Intervention for ChildrenWith
Vesicoureteral Reflux trial and the Careful Urinary Tract Infection Evaluation Study). Children
younger than 6 years with a first or second UTI were followed up for 2 years.
EXPOSURE Duration of the child’s fever prior to initiation of antimicrobial therapy for the
index UTI.
MAIN OUTCOMES ANDMEASURES New renal scarring defined as the presence of photopenia
plus contour change on a late dimercaptosuccinic acid renal scan (obtained at study exit) that
was not present on the baseline scan.
RESULTS Of the 482 children included in the analysis, 434 were female (90%), 375 were
white (78%), and 375 had vesicoureteral reflux (78%). Themedian age was 11 months. A total
of 35 children (7.2%) developed new renal scarring. Delay in the initiation of antimicrobial
therapy was associated with renal scarring; the median (25th, 75th percentiles) duration of
fever prior to initiation of antibiotic therapy in those with and without renal scarring was
72 (30, 120) and 48 (24, 72) hours, respectively (P = .003). Older age (OR, 1.03; 95% CI,
1.01-1.05), Hispanic ethnicity (OR, 5.24; 95% CI, 2.15-12.77), recurrent urinary tract infections
(OR, 0.97; 95% CI, 0.27-3.45), and bladder and bowel dysfunction (OR, 6.44; 95% CI,
2.89-14.38) were also associated with new renal scarring. Delay in the initiation of
antimicrobial therapy remained significantly associated with renal scarring even after
adjusting for these variables.
CONCLUSIONS AND RELEVANCE Delay in treatment of febrile UTIs and permanent renal
scarring are associated. In febrile children, clinicians should not delay testing for UTI.
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I nchildrenwith febrile urinary tract infections (UTIs), a de-lay in the initiation of antimicrobial therapy has been hy-pothesized to increase the risk and extent of renal scar-
ring. This hypothesis has beenexamined in6previous studies
with conflicting results1-6; 4 studies2-4,6 suggest that delay in
initiation of antimicrobial therapy and the extent or severity
of renal scarring are associated,whereas 2 studies1,5 foundno
such association. The latter 2 studies differed from the other
studies in that they includedonly a subset of childrenwith fe-
brile UTIs (ie, thosewith photopenia on an early dimercapto-
succinic acid [DMSA] scan), which limits their usefulness in
testing this hypothesis.
Our objective was to determine, in a well-characterized
sample of childrenwith febrileUTIs,whether delay in the ini-
tiation of antimicrobial therapy was associated with the oc-
currence and severity of renal scarring and to determine
whether these associations persisted after adjusting for po-
tential confounding factors.
Methods
Toevaluate thequestionposed in this study,weuseddata from
2 longitudinal studies (theRandomized Intervention for Chil-
drenWithVesicoureteral Reflux [RIVUR] trial and the Careful
UrinaryTract InfectionEvaluationStudy [CUTIE] study). Chil-
dren in these studieswere aged2 to 72months, presented fol-
lowing their first or second UTI at primary and subspecialty
care settings throughout theUnited States, andwereprospec-
tively followed up for 2 years. The methods for these studies
have been previously reported.7-9 Briefly, children with vesi-
coureteral reflux were enrolled in the RIVUR (n = 607) trial
whereas thosewithout vesicoureteral refluxwere enrolled in
the parallel CUTIE study (n = 195). Not all sites participating
in the RIVUR trial participated in the CUTIE study. The fol-
low-up and data collection forms in both studies were identi-
cal with the exception that children in the RIVUR trial
received (1) a study drug (antimicrobial prophylaxis or pla-
cebo), (2) a DMSA scan at the 12-month follow-up visit, and
(3)avoidingcystourethrogramat the24-month follow-upvisit.
Institutional review boards at all participating sites approved
the RIVUR and CUTIE study protocols, and written informed
consentwasobtained fromtheparentsof all participating chil-
dren. At the time of enrollment in the studies, we asked par-
ents about thedurationof their child’s fever (inhours as a con-
tinuousvariable)prior to initiationof antimicrobial therapy for
the index UTI. Delay in the initiation of therapy was defined
as thedurationof timebetween theonsetof fever and the start
of antimicrobial therapy. In both studies, children had a tech-
netium Tc 99mDMSA renal scan at baseline and a late DMSA
scan either at the 24-month follow-up visit or 3 to 4 months
after beingwithdrawn fromthe studyowing to recurrentUTIs
(ie, met predetermined criteria for treatment failure). We de-
fined new renal scarring as the presence of areas of photope-
nia plus contour changes on a late DMSA scan that were not
present on the baseline scan. The extent of renal scarringwas
quantifiedusing thesystemdevelopedbytheRIVURtrial steer-
ing committee in which the renal parenchyma is divided into
13 segments.8 The studiesusedSAS, version9.3, for the analy-
sis (SAS Institute Inc).
For this analysis,weexcludedchildrenwithno fever (tem-
perature <38°C), childrenwithmissing information about de-
lay in the initiation of therapy, and childrenwho did not have
a lateDMSAscan.Weused theWilcoxon rank sumtest to com-
pare themediandelay in the initiationof antimicrobial therapy
in children with and without evidence of renal scarring and
theKruskall-Wallis test toexamine theassociationbetweende-
lay in the initiation of antimicrobial therapy and the number
of segments affected. We fitted logistic models with renal
scarring as the dependent variable. Predictor variables were
delay in the initiation of antimicrobial therapy, age, sex, race/
ethnicity, vesicoureteral reflux, bladder and bowel dysfunc-
tion, parental education, public assistance, history of UTI (no
prior UTIs vs 1 prior UTI), type of infecting organism (Escher-
ichia colivsother), interimUTIs betweenenrollment and time
ofDMSAscan, treatment group, andheightof fever at the time
of the index UTI (temperature <39°C vs ≥39°C). Univariable
models were considered first, and covariates with associa-
tion significant at a 0.20 level and covariates considered im-
portant (ie, treatment group and study)were included in con-
structing the multivariable model. We also constructed
alternate models using different criteria (eg, with and with-
out interim UTIs included or using P < .10 for inclusion) to
assess the robustness of our findings.
Results
Of the 802 children enrolled in theRIVUR andCUTIE studies,
we excluded 132 children who were afebrile at the time of
presentation for the index UTI, 12 children with missing du-
rationof fever, and 176childrenwithmissing lateDMSAscans,
leaving482 children.Dimercaptosuccinic acid scanswere ob-
tained200to1060daysafteran indexUTI.Themean (SD) time
between the indexUTI andenrollmentwas58 (29)days. Com-
paredwith childrenwhowere excluded, those included in the
study were significantly younger (median age 11 months for
includedchildrenvs 16months for excludedchildren) and sig-
nificantlymore likely to have vesicoureteral reflux (78% [375
of482] vs 72%[232of 320]), not tohaveahistoryofUTIs (94%
Key Points
Question Is delay in the initiation of antimicrobial therapy for
urinary tract infections in children associated with the occurrence
of new renal scarring?
Findings In this cohort study, delay in the initiation of
antimicrobial therapy was significantly associated with renal
scarring and remained so after adjusting for potential confounding
variables (age, race, ethnicity, infecting organism, history of
urinary tract infection, interim urinary tract infection, and study
group). Median delay in initiation of antibiotic treatment in those
with and without renal scarring was 72 and 48 hours, respectively.
Meaning In febrile children, clinicians should not delay testing for
urinary tract infections.
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Table 1. Demographic and Clinical Characteristics of 482 ChildrenWith Febrile Urinary Tract Infection
According to Delay in the Initiation of Antimicrobial Therapy
Characteristics
Overall
(n = 482)
Duration of Fever Prior to
Treatment, No. (%)
P Value
<48 h
(n = 304)
≥48 h
(n = 178)
Age, mo
2-11 259 (54) 191 (63) 68 (38)
<.00112-35 135 (28) 67 (22) 68 (38)
36-72 88 (18) 46 (15) 42 (24)
Sex
Male 48 (10) 32 (11) 16 (9)
.59
Female 434 (90) 272 (89) 162 (91)
Race
White 375 (78) 234 (77) 141 (79)
.47Nonwhite 101 (21) 67 (22) 34 (19)
Missing 6 (1) 3 (1) 3 (2)
Ethnicity
Hispanic 74 (15) 47 (15) 27 (15)
.94Non-Hispanic 406 (84) 256 (84) 150 (84)
Missing 2 (0) 1 (0) 1 (1)
Parental education
High school graduate or lower 139 (29) 87 (29) 52 (29)
.89Greater than high school 340 (71) 215 (71) 125 (70)
Missing 3 (1) 2 (1) 1 (1)
Public assistance
Yes 166 (34) 107 (35) 59 (33)
.72No 312 (65) 196 (64) 116 (65)
Missing 4 (1) 1 (0) 3 (2)
Highest reflux of both ureters
0 107 (22) 69 (23) 38 (21)
.63
1 33 (7) 18 (6) 15 (8)
2 147 (30) 88 (29) 59 (33)
3 155 (32) 102 (34) 53 (30)
4 37 (8) 25 (8) 12 (7)
Missing 3 (1) 2 (1) 1 (1)
No. of UTIs prior to the index UTI
0 453 (94) 287 (94) 166 (93)
.61
1 29 (6) 17 (6) 12 (7)
Infecting organism
Escherichia coli 442 (92) 283 (93) 159 (89)
.15
Non–Escherichia coli 40 (8) 21 (17) 19 (11)
Highest temperature reported within 24 h of index UTI
<39°C 131 (27) 98 (32) 33 (19)
.001
≥39°C 351 (73) 206 (68) 145 (81)
Bladder and bowel dysfunction
No or not toilet trained 433 (90) 274 (90) 159 (89)
.75Yes 46 (10) 28 (9) 18 (10)
Missing 3 (1) 2 (1) 1 (1)
Interim UTIs
No 390 (81) 249 (82) 141 (79)
.47
Yes 92 (19) 55 (18) 37 (21)
Treatment group and study
CUTIE 107 (22) 69 (23) 38 (21)
.79
RIVUR
Placebo 195 (40) 125 (41) 70 (39)
Active 180 (37) 110 (36) 70 (39)
Abbreviations: CUTIE, Careful Urinary
Tract Infection Evaluation Study;
RIVUR, Randomized Intervention for
ChildrenWith Vesicoureteral Reflux;
UTI, urinary tract infection.
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[453 of 482] vs 86% [275 of 320]), and not to be toilet trained
at the timeofenrollment (82%[393of482]vs69%[215of320]).
Thedemographic andclinical characteristics of the sample are
further described in Table 1. Children included in the study
weremore likely to have adelay in the initiation of antimicro-
bial therapy (median of 56.3 hours in included children com-
paredwith 50.3 hours in excluded children), although this as-
sociation was not significant.
A total of 35 children (7.2%) hadnew renal scarring on the
outcome DMSA scan. Delay in the initiation of antimicrobial
therapy and renal scarringwere associated; themedian (25th,
75th percentiles) duration of fever in those with and without
renal scarring was 72 (30, 120) and 48 (24, 72) hours, respec-
tively (P = .003). The proportion of children with new renal
scarring increasedwith increasingdurationof feverbefore ini-
tiation of antimicrobial therapy (Figure).Table 2 presents the
univariateassociationofcovariatesandnewrenal scarring, and
Table 3 presents the results of the multivariable logistic re-
gressionanalysis. Becausebladder andboweldysfunction sta-
tus andagewerehighly correlated,weonly includedage in the
multivariable model. Delay in the initiation of antimicrobial
therapy remained significantly associatedwith renal scarring
even after adjusting for age (OR, 1.03; 95% CI, 1.01-1.05), race
(OR,0.62;95%CI,0.20-1.89), ethnicity (OR,5.24;95%CI, 2.15-
12.77), infecting organism (OR, .57; 95% CI, 0.20-1.63), previ-
ous UTI (OR, 0.97; 95% CI, 0.27-3.45), and interim UTIs (OR,
6.44; 95% CI, 2.89-14.38). For every hour that antimicrobial
therapy is delayed, we expect the odds of new renal scarring
to increase by 0.8%. In all alternatemodels considered, delay
in initiation of antimicrobial therapy and new renal scarring
remained significant.
Theassociationbetweendelay in initiationof therapyand
number of segments with renal scarring (OR, 1.005; 95% CI,
1.001-1.01; P = .03) became nonsignificant (P = .12) after ad-
justing forpotential confounders.Onlyheightof fever (OR,4.13;
95% CI, 1.72-9.94; P = .002), and interim UTIs (OR, 1.95; 95%
CI, 1.05-3.64; P = .04) remained significantly associatedwith
the number of segments with renal scarring.
Discussion
In children with a febrile UTI, we found that delay in initia-
tion of antimicrobial therapy was associated with the devel-
opment of renal scarring. After adjusting other covariates,we
estimate that a delay of 48 hours or more would increase the
odds of new renal scarring by about 47%. The concordance of
our findingwith previous studies2-4 that included similar pa-
tients and the robustness of our main finding even after con-
trolling for other potential confounding factors (including in-
terim UTIs, previous UTIs, and age) strongly support the
hypothesis thatdelay in the initiationof antimicrobial therapy
and the development of renal scars are related. Data from ex-
perimentally induced pyelonephritis in animals provide fur-
ther support. Miller and Phillips10 injected bacteria into kid-
neys of rats andwaited 8, 24, 48, 72, 96, and 120hours before
initiating antibiotic treatment; the extent of renal scarring as
evidencedongrosspathologyanddelay in the initiationof an-
timicrobial therapy were strongly associated. Studies per-
formed by Ransley and Risdon11 and Glauser et al12 had simi-
lar findings.
Although 1 large studybyHewitt et al5 failed to find an as-
sociation between delay in the initiation of antimicrobial
therapy and development of renal scars, this study only in-
cluded children with pyelonephritis confirmed by DMSA. In
our view, this is a limitation. Because an acute-phase DMSA
scan is not usually obtained in clinical practice, findings from
this study cannot be extrapolated to all childrenwith a febrile
UTI. Furthermore, even if early antibiotic treatment does not
reduce rates of renal scarringonce the renal parenchyma is in-
volved (and can be visualized on a DMSA scan), early treat-
ment could still be effective by reducing the risk of renal pa-
renchymal involvement in the first place. If so, one would
expect a study that included only children with known renal
involvement to find no association between delay in the ini-
tiation of antimicrobial therapy and renal scarring even if the
2 were causally linked. A second study by Doganis et al1 also
failed to find an association between delay in the initiation of
antimicrobial therapy and the occurrence of renal scarring,
likelybecause theassociationbetween treatmentdelayand re-
nal scarring was only examined in the subset of patients who
alreadyhad renal involvement.Ofnote, the latter study found
that children inwhomantimicrobial therapywasdelayedhad
a substantially higher risk of acute pyelonephritis,which sup-
ports the hypothesis that the detrimental effect of treatment
delay occurs before pyelonephritis is detectable on a DMSA
scan. The later 2 studies also differed from our study in that
they includedaveryhighproportionofboys.Becauseboysare
substantiallymore likely tohave congenital lesions that could
bemistaken for acquired renal scarring13 and because neither
study examined the incidence of new renal scarring, it may
have been more difficult for these studies to detect an asso-
ciation between treatment delay and renal scarring.
Several limitations are notable. First, we asked parents
about the duration of fever before initiation of antimicrobial
therapy at the enrollment visit, which occurred, on average,
58 days after the index UTI. Therefore, parental recollection
Figure. Percentage of ChildrenWith NewRenal Scarring According to
Delay in the Initiation of Antimicrobial Therapy
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Table 2. NewRenal Scarring According to Selected Clinical and Demographic Characteristics
Characteristics
Renal Scarring, No./No. (%)
(n = 35) OR (95% CI) P Value
Age, mo
2-11 11/259 (4) 0.23 (0.10-0.54)
.00312-35 10/135 (7) 0.42 (0.18-1.00)
36-72 14/88 (16) 1 [Reference]
Sex
Male 2/48 (4) 1 [Reference]
.39
Female 33/434 (8) 1.89 (0.44-8.15)
Race
White 31/375 (8) 2.19 (0.75-6.34)
.15Nonwhite 4/101 (4) 1 [Reference]
Missing 0/6 (0)
Ethnicity
Hispanic 11/74 (15) 2.78 (1.30-5.56)
.01Non-Hispanic 24/406 (6) 1 [Reference]
Missing 0/2 (0)
Parental education
High school graduate or lower 11/139 (8) 1.13 (0.54-2.38)
.74Greater than high school 24/340 (7) 1 [Reference]
Missing 0/3 (0)
Public assistance
Yes 11/166 (7) 0.85 (0.41-1.79)
.67No 24/312 (8) 1 [Reference]
Missing 0/4 (0)
Highest reflux of both ureters
None 5/107 (5) 0.56 (0.21-1.48)
.24Any 30/372 (8) 1 [Reference]
Missing 0/3 (0)
Infecting organism
Escherichia coli 29/442 (7) 0.40 (0.15-1.02)
.06
Non–Escherichia coli 6/40 (15) 1 [Reference]
No. of prior UTIs
0 31/453 (7) 0.46 (0.15-1.40)
.17
1 4/29 (14) 1 [Reference]
Highest temperature reported within 24
h of index UTI
<39°C 8/131 (6) 0.78 (0.35-1.77)
.55
≥39°C 27/351 (8) 1 [Reference]
Bladder and bowel dysfunction
No or not toilet trained 27/433 (6) 0.32 (0.13-0.74)
.01Yes 8/46 (17) 1 [Reference]
Missing 0/3 (0)
Duration of fever prior to treatment, ha
≤24 8/194 (4) 0.26 (0.11-0.63)
.02
>24-28 6/112 (5) 0.34 (0.13-0.90)
>48-72 6/74 (8) 0.52 (0.19-1.42)
>72 15/104 (14) 1 [Reference]
Interim UTIs
No 17/390 (4) 0.19 (0.09-0.38)
<.001
Yes 18/92 (20) 1 [Reference]
Treatment group and study
CUTIE 5/107 (5) 0.58 (0.20-1.66)
.51
RIVUR
Placebo 16/195 (8) 1.06 (0.50-2.24)
Active 14/180 (8) 1 [Reference]
Abbreviations: CUTIE, Careful Urinary
Tract Infection Evaluation Study;
OR, odds ratio; RIVUR, Randomized
Intervention for ChildrenWith
Vesicoureteral Reflux; UTI, urinary
tract infection.
a Data were collected as a continuous
variable.
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of the duration of fever before treatment may not have been
precise. However, only 12 children were excluded from the
analysis because their parents were unable to estimate the
duration of fever prior to treatment. In addition, we asked
about delay in the initiation of antimicrobial therapy before
the outcome was determined (ie, before the baseline DMSA
scan was performed). Accordingly, it is unlikely that the
imprecision in the data could explain differences observed
in children with and without renal scarring. A second limita-
tion is that children included in the study were younger and
were more likely to have vesicoureteral reflux than children
who were excluded. Nevertheless, no significant differences
in time to antimicrobial therapy were noted between chil-
dren who were included and children who were excluded.
Finally, the number of children with new renal scarring was
relatively low, limiting our confidence in the multivariate
models.
Our findings have several implications. First, because
prompt testing and treatment appeared to be associated
with a reduced risk of renal scarring, clinicians should not
delay testing in febrile children who could potentially have a
UTI. Someauthorshave suggested that testing forUTIs should
bedelayeduntil feverhasbeenpresent for at least4 to5days.14
Careful examination of the American Academy of Pediatrics
guidelines15 and other available diagnostic algorithms16 re-
veals that many febrile children meet criteria for testing be-
fore the48-hourmark.Forexample, 1meta-analysis foundthat
white female children younger than 2 years who had a fever
formore than24hourshadaprobabilityofUTI thatwashigher
than the testing threshold for most clinicians.16 Second, par-
ents of children who are at high risk for febrile UTI recur-
rences (eg, childrenwith vesicoureteral reflux, bladder bowel
dysfunction, or previous UTIs) should be counseled to bring
their child promptly for evaluation of subsequent febrile ill-
nesses. Third, our data do not support the notion frequently
held by clinicians that the risk of renal scarring is higher in
younger children. In fact, this very notion may be partly re-
sponsible for the higher likelihood of treatment delay and as-
sociated renal scarring in older children.
Conclusions
A growing body of evidence suggests that delay in treatment
of febrile UTIs and permanent renal scarring are associated.
These data may help clinicians make more informed deci-
sions regarding theneed for diagnostic testing forUTIs in chil-
dren presenting with fever.
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